PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
NASDAQ:PTCT - US69366J2006 - Common Stock
49.94 USD
+0.48 (+0.97%)
Taking everything into account, PTCT scores 6 out of 10 in our fundamental rating. PTCT was compared to 547 industry peers in the Biotechnology industry. PTCT has an average financial health and profitability rating. PTCT is growing strongly while it is still valued neutral. This is a good combination! These ratings could make PTCT a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year PTCT was profitable.
In the past year PTCT had a positive cash flow from operations.
In the past 5 years PTCT always reported negative net income.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTCT's Return On Assets of 23.89% is amongst the best of the industry. PTCT outperforms 97.44% of its industry peers.
Looking at the Return On Invested Capital, with a value of 34.54%, PTCT belongs to the top of the industry, outperforming 99.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.89% | ||
| ROE | N/A | ||
| ROIC | 34.54% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 35.65%, PTCT belongs to the best of the industry, outperforming 97.26% of the companies in the same industry.
PTCT has a better Operating Margin (49.70%) than 99.45% of its industry peers.
With an excellent Gross Margin value of 97.09%, PTCT belongs to the best of the industry, outperforming 96.53% of the companies in the same industry.
PTCT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.7% | ||
| PM (TTM) | 35.65% | ||
| GM | 97.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
Compared to 1 year ago, PTCT has more shares outstanding
PTCT has more shares outstanding than it did 5 years ago.
PTCT has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.84 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.84, PTCT is in the better half of the industry, outperforming 68.37% of the companies in the same industry.
The Debt to FCF ratio of PTCT is 3.44, which is a good value as it means it would take PTCT, 3.44 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PTCT (3.44) is better than 93.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.44 | ||
| Altman-Z | 1.84 |
ROIC/WACC4.41
WACC7.84%
2.3 Liquidity
PTCT has a Current Ratio of 3.62. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PTCT (3.62) is comparable to the rest of the industry.
PTCT has a Quick Ratio of 3.57. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a Quick ratio (3.57) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.57 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 226.85%, which is quite impressive.
Looking at the last year, PTCT shows a very strong growth in Revenue. The Revenue has grown by 96.00%.
PTCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.32% yearly.
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
3.2 Future
PTCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.99% yearly.
The Revenue is expected to grow by 16.48% on average over the next years. This is quite good.
EPS Next Y227.55%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue Next Year114.29%
Revenue Next 2Y3.53%
Revenue Next 3Y10.2%
Revenue Next 5Y16.48%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.81, the valuation of PTCT can be described as reasonable.
PTCT's Price/Earnings ratio is rather cheap when compared to the industry. PTCT is cheaper than 97.08% of the companies in the same industry.
PTCT is valuated cheaply when we compare the Price/Earnings ratio to 27.08, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
PTCT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PTCT is cheaper than 98.35% of the companies in the same industry.
99.45% of the companies in the same industry are more expensive than PTCT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.69 | ||
| EV/EBITDA | 3.72 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 24.02% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y18.49%
EPS Next 3Y24.02%
5. Dividend
5.1 Amount
PTCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PTCT (8/27/2025, 3:23:54 PM)
49.94
+0.48 (+0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.55%
Inst Owner Change0.77%
Ins Owners0.63%
Ins Owner Change1.03%
Market Cap3.97B
Analysts78.26
Price Target67.93 (36.02%)
Short Float %7.77%
Short Ratio5.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2381.07%
Min EPS beat(2)19.15%
Max EPS beat(2)4742.99%
EPS beat(4)3
Avg EPS beat(4)1136.58%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)4
Avg EPS beat(8)542.24%
EPS beat(12)4
Avg EPS beat(12)345.78%
EPS beat(16)4
Avg EPS beat(16)251.94%
Revenue beat(2)2
Avg Revenue beat(2)293.56%
Min Revenue beat(2)1.78%
Max Revenue beat(2)585.33%
Revenue beat(4)3
Avg Revenue beat(4)147.19%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.29%
Revenue beat(12)7
Avg Revenue beat(12)50.33%
Revenue beat(16)10
Avg Revenue beat(16)38.97%
PT rev (1m)6.5%
PT rev (3m)6.56%
EPS NQ rev (1m)-2.14%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)10.83%
EPS NY rev (3m)56.95%
Revenue NQ rev (1m)-2.32%
Revenue NQ rev (3m)-3.46%
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)10.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.81 | ||
| Fwd PE | N/A | ||
| P/S | 2.25 | ||
| P/FCF | 5.69 | ||
| P/OCF | 5.63 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.72 |
EPS(TTM)5.67
EY11.35%
EPS(NY)-3.58
Fwd EYN/A
FCF(TTM)8.78
FCFY17.58%
OCF(TTM)8.87
OCFY17.76%
SpS22.22
BVpS-2.6
TBVpS-5.45
PEG (NY)0.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.89% | ||
| ROE | N/A | ||
| ROCE | 43.72% | ||
| ROIC | 34.54% | ||
| ROICexc | 4029.4% | ||
| ROICexgc | N/A | ||
| OM | 49.7% | ||
| PM (TTM) | 35.65% | ||
| GM | 97.09% | ||
| FCFM | 39.52% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.44 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 26.13% | ||
| Cap/Sales | 0.42% | ||
| Interest Coverage | 203.36 | ||
| Cash Conversion | 77.86% | ||
| Profit Quality | 110.85% | ||
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.57 | ||
| Altman-Z | 1.84 |
F-Score8
WACC7.84%
ROIC/WACC4.41
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y227.55%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
Revenue Next Year114.29%
Revenue Next 2Y3.53%
Revenue Next 3Y10.2%
Revenue Next 5Y16.48%
EBIT growth 1Y546.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year722.81%
EBIT Next 3Y67.86%
EBIT Next 5YN/A
FCF growth 1Y350.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y384.63%
OCF growth 3YN/A
OCF growth 5YN/A